{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:24:53Z","timestamp":1793287493428,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113C-152"],"award-info":[{"award-number":["V113C-152"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112D64-001-MY2-2"],"award-info":[{"award-number":["V112D64-001-MY2-2"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2314-B-075-016 MY3"],"award-info":[{"award-number":["110-2314-B-075-016 MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016173","name":"Female Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-075 -057 -MY3"],"award-info":[{"award-number":["113-2314-B-075 -057 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.tjog.2024.07.014","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T19:00:28Z","timestamp":1725994828000},"page":"651-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer"],"prefix":"10.1016","volume":"63","author":[{"given":"Che-Wei","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Hsien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ling","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2024.07.014_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tjog.2024.04.005","article-title":"Cervical cancer: Part I human papilloma virus vaccination in Taiwan","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib2","article-title":"Bevacizumab is associated with a higher gastrointestinal\/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy","volume":"15","author":"Yang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.07.014_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tjog.2024.03.002","article-title":"Immunohistochemical staining for cytology-based cervical cancer screening","volume":"63","author":"Chang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.tjog.2024.07.014_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ijgo.13865","article-title":"Cancer of the cervix uteri: 2021 update","volume":"155","author":"Bhatla","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.07.014_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ygyno.2014.06.001","article-title":"The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer","volume":"134","author":"He","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3892\/mco.2013.112","article-title":"Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG\/TGCU Intergroup Surveillance","volume":"1","author":"Shimada","year":"2013","journal-title":"Mol Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.tjog.2024.07.014_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ijgo.13871","article-title":"Progress in the pathological arena of gynecological cancers","volume":"155","author":"McCluggage","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.07.014_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tjog.2023.11.008","article-title":"Mutational analysis of PDGFRA oncogene in high-grade neuroendocrine carcinoma of the uterine cervix in twelve Taiwanese women","volume":"63","author":"Chang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"Endometrial cancer staging subcommittee, FIGO women's cancer committee. FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.07.014_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tjog.2023.11.005","article-title":"Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.tjog.2023.09.017","article-title":"Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125","volume":"62","author":"Yang","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/JCMA.0000000000001006","article-title":"Long-term outcome of minimally invasive staging surgery for clinical stage I endometrial cancer: a single institute experience in Taiwan","volume":"87","author":"Lu","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/JCMA.0000000000000985","article-title":"The relationship between serum CA-125 level and recurrence in surgical stage I endometrial cancer patients","volume":"86","author":"Wu","year":"2023","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tjog.2023.07.034","article-title":"The role of sialylation in gynecologic cancers","volume":"62","author":"Yang","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JCMA.0000000000001069","article-title":"Minimally invasive approach is preferred for clinical stage 1 endometrioid-type endometrial cancer","volume":"87","author":"Wang","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijgo.15315","article-title":"Impact of sentinel lymph node mapping on survival in patients with high-risk endometrial cancer in the early stage: a matched cohort study","volume":"165","author":"Jaafar","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.07.014_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ijgo.15263","article-title":"Nomograms for predicting overall survival and cancer-specific survival of endometrioid ovarian carcinoma: a retrospective cohort study from the SEER database","volume":"165","author":"Wang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2024.07.014_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tjog.2024.08.001","article-title":"Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JCMA.0000000000000910","article-title":"A\u00a0retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients","volume":"86","author":"Ho","year":"2023","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/JCMA.0000000000001104","article-title":"Effectiveness of early palliative care in patients with head and neck cancer in Taiwan","volume":"87","author":"Chen","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/JCMA.0000000000001085","article-title":"Enhancing regional control in p16-negative oropharyngeal cancer: a propensity score-matched analysis of upfront neck dissection and definitive chemoradiotherapy","volume":"87","author":"Lee","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/JCMA.0000000000001004","article-title":"Comparison of wide and narrow gastric conduit in esophageal cancer surgery","volume":"86","author":"Chen","year":"2023","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/JCMA.0000000000001121","article-title":"Induction chemotherapy followed by transoral laser microsurgery with or without adjuvant therapy for advanced hypopharyngeal cancer patients: a preliminary result","volume":"87","author":"Chang","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/life14060667","article-title":"Abdominal parietal metastasis from cervical cancer: a review of one of the most uncommon sites of recurrence including a report of a new case","volume":"14","author":"Dicu-Andreescu","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.tjog.2024.07.014_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/IGC.0b013e3181d2c234","article-title":"Outcome of patients with incomplete resection after surgery for stage IB2\/II cervical carcinoma with chemoradiation therapy","volume":"20","author":"Uzan","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.07.014_bib27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12885-018-4232-x","article-title":"The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy\/chemoradiotherapy: a meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tjog.2024.07.014_bib28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/IJN.S290438","article-title":"Application of radiosensitizers in cancer radiotherapy","volume":"16","author":"Gong","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.tjog.2024.07.014_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1363121","article-title":"Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot","volume":"12","author":"Han","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.tjog.2024.07.014_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s40258-024-00884-2","article-title":"Informing structural assumptions for three state oncology cost-effectiveness models through model efficiency and fit","author":"Muston","year":"2024","journal-title":"Appl Health Econ Health Pol"},{"key":"10.1016\/j.tjog.2024.07.014_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(23)00052-9","article-title":"Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib34","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1111\/cas.15479","article-title":"Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: results from KEYNOTE-826","volume":"113","author":"Nishio","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.tjog.2024.07.014_bib35","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2024.07.014_bib36","first-page":"1","article-title":"Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer","volume":"29","author":"Fontenot","year":"2024","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.tjog.2024.07.014_bib37","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2024.07.014_bib38","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2024.07.014_bib39","first-page":"CD013348","article-title":"Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer","volume":"3","author":"Chuai","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tjog.2024.07.014_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.tjog.2024.07.014_bib41","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.tjog.2024.07.014_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2024.07.014_bib43","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1200\/JCO.22.02852","article-title":"Randomized phase III study comparing neoadjuvant chemotherapy followed by surgery versus chemoradiation in stage IB2-IIB cervical cancer: EORTC-55994","volume":"41","author":"Kenter","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12905-024-03024-z","article-title":"Outcomes of neoadjuvant chemotherapy and radical hysterectomy for locally advanced cervical cancer at Kigali University Teaching Hospital, Rwanda: a retrospective descriptive study","volume":"24","author":"Ngabonziza","year":"2024","journal-title":"BMC Wom Health"},{"key":"10.1016\/j.tjog.2024.07.014_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1470-2045(23)00576-4","article-title":"Is there finally a place for neoadjuvant treatment in locally advanced cervical cancer?","volume":"25","author":"Pautier","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib47","first-page":"84","article-title":"Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer","volume":"21","author":"Romero","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tjog.2021.03.008","article-title":"Neoadjuvant chemotherapy increases the 5-year overall survival of patients with resectable cervical cancer: a systematic review and meta-analysis","volume":"60","author":"Xu","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12905-024-03215-8","article-title":"The role of neoadjuvant chemotherapy before radical surgery in stage IB2\/IIA2 squamous cell cervical cancers","volume":"24","author":"Alci","year":"2024","journal-title":"BMC Wom Health"},{"key":"10.1016\/j.tjog.2024.07.014_bib50","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3390\/medicina60060871","article-title":"The role of lymph node downstaging following neoadjuvant treatment in a group of patients with advanced stage cervical cancer","volume":"60","author":"Dicu-Andreescu","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.tjog.2024.07.014_bib51","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12885-024-12411-6","article-title":"Neoadjuvant chemotherapy followed by surgery versus concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma: a retrospective cohort study","volume":"24","author":"Pan","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tjog.2024.07.014_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/a-2279-3163","article-title":"f\u00fcr die Kommission Uterus der AGO. Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Neoadjuvant Chemotherapy Prior to Definitive Radiochemotherapy in Patients with Locally Advanced Cervical Cancer","volume":"84","author":"Tempfer","year":"2024","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.tjog.2024.07.014_bib53","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2024.04.023","article-title":"Meta-analysis of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer","volume":"297","author":"Wang","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.tjog.2024.07.014_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/JCMA.0000000000000855","article-title":"Neoadjuvant therapy","volume":"86","author":"Wang","year":"2023","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/JCMA.0000000000000883","article-title":"Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy","volume":"86","author":"Chiu","year":"2023","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib56","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCMA.0000000000001034","article-title":"Preoperative systemic inflammation response index: clinicopathologic predictor of pathological complete response in HER2-positive breast cancer patients receiving neoadjuvant systemic therapy","volume":"87","author":"Wu","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib57","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.940545","article-title":"Efficacy analysis of neoadjuvant versus adjuvant cisplatin-paclitaxel regimens for initial treatment of FIGO stages IB3 and IIA2 cervical cancer","volume":"29","author":"Tao","year":"2023","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.tjog.2024.07.014_bib58","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1038\/s41598-023-49539-7","article-title":"The prognostic value of radiological and pathological lymph node status in patients with cervical cancer who underwent neoadjuvant chemotherapy and followed hysterectomy","volume":"14","author":"Lou","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjog.2024.07.014_bib59","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1186\/s12885-022-10355-3","article-title":"Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tjog.2024.07.014_bib60","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.tjog.2014.05.001","article-title":"Outcome of patients with bulky IB (\u2265 6 cm) cervical squamous cell carcinoma with and without cisplatin-based neoadjuvant chemotherapy","volume":"53","author":"Wang","year":"2014","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib61","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.3390\/ijerph16203833","article-title":"Radical hysterectomy after neoadjuvant chemotherapy for locally bulky-size cervical cancer: a retrospective comparative analysis between the robotic and abdominal approaches","volume":"16","author":"Liu","year":"2019","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.tjog.2024.07.014_bib62","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.tjog.2023.05.001","article-title":"Foley catheter management in laparoscopic surgery is one of the critical components for enhanced recovery after surgery (ERAS) programs","volume":"62","author":"Chang","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib63","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/JCMA.0000000000000948","article-title":"Pelvic organ prolapse: minimally invasive approach","volume":"86","author":"Li","year":"2023","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib64","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/JCMA.0000000000001080","article-title":"Sugammadex shortens operation time and improves operation turnover efficacy in video-assisted thoracoscopic surgery","volume":"87","author":"Lin","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JCMA.0000000000000933","article-title":"Comparing outcomes of ovarian cystectomy by vaginal natural orifice transluminal endoscopic surgery versus laparoendoscopic single-site surgery: a retrospective cohort study","volume":"86","author":"Chang","year":"2023","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib66","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/diagnostics12051230","article-title":"Pretreatment radiologically enlarged lymph nodes as a significant prognostic factor in clinical stage IIB cervical cancer: evidence from a Taiwanese tertiary care center in reaching consensus","volume":"12","author":"Liu","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.tjog.2024.07.014_bib67","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2024.07.014_bib68","article-title":"Neoadjuvant pembrolizumab+chemotherapy\/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: quality-of-Life results from randomized KEYNOTE-522 study","volume":"24","author":"Dent","year":"2024","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.tjog.2024.07.014_bib69","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2024.07.014_bib70","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib71","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tjog.2024.05.004","article-title":"The selection of immune checkpoint inhibitors of programmed cell death (anti-PD-1) and its ligand (anti-PD-L1) makes matters more challenges for clinical practice","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib72","doi-asserted-by":"crossref","first-page":"A224","DOI":"10.1136\/ijgc-2022-igcs.512","article-title":"TP003\/#1533 MITO CERV3_phase II study on carboplatin-paclitaxel-pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer","volume":"32","author":"Salutari","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"24","key":"10.1016\/j.tjog.2024.07.014_bib73","first-page":"S0936","article-title":"Pooled rate of pseudoprogression, patterns of response, and tumor burden analysis in patients undergoing immunotherapy oncologic trials for different malignancies","volume":"10","author":"Morrissey","year":"2024","journal-title":"Clin Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217095","article-title":"Less is more:\u00a0exploring neoadjuvant immunotherapy as a de-escalation strategy in head\u00a0and neck squamous cell carcinoma treatment","volume":"598","author":"Cao","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.tjog.2024.07.014_bib75","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.tjog.2024.07.014_bib76","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/ijgc-2023-004580","article-title":"New windows of surgical opportunity for gynecological cancers in the era of targeted therapies","volume":"34","author":"Peters","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.07.014_bib77","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/biomedicines12061291","article-title":"Efficacy and safety of atezolizumab as a PD-L1 inhibitor in the treatment of cervical cancer: a systematic review","volume":"12","author":"Velimirovici","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.tjog.2024.07.014_bib78","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.21037\/apm.2019.10.03","article-title":"Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients","volume":"9","author":"Lau","year":"2020","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.tjog.2024.07.014_bib79","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/s21010122","article-title":"AF-SENet: classification of cancer in cervical tissue pathological images based on fusing deep convolution features","volume":"21","author":"Huang","year":"2020","journal-title":"Sensors"},{"key":"10.1016\/j.tjog.2024.07.014_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1109\/TMI.2022.3202248","article-title":"A\u00a0ViT-AMC network with adaptive model fusion and multiobjective optimization for interpretable laryngeal tumor grading from histopathological images","volume":"42","author":"Huang","year":"2023","journal-title":"IEEE Trans Med Imag"},{"key":"10.1016\/j.tjog.2024.07.014_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1362281","article-title":"Prognostic analysis of stage IIIC1p cervical cancer patients","volume":"14","author":"Gao","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib82","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","article-title":"Validation of the 2018 FIGO cervical cancer staging system","volume":"152","author":"Matsuo","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2024.01.032","article-title":"The emerging and challenging role of PD-L1 in patients with gynecological cancers: an updating review with clinico-pathological considerations","volume":"184","author":"Santoro","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib84","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"de Ruiter","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.tjog.2024.07.014_bib85","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/JCMA.0000000000001122","article-title":"Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part I","volume":"87","author":"Wang","year":"2024","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib86","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab\u00a0+ chemotherapy versus placebo\u00a0+ chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib87","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/ijgc-2022-004214","volume":"33","author":"Ishikawa","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.07.014_bib88","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study","volume":"41","author":"Vergote","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib89","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1078-0432.CCR-23-1829","article-title":"Phase I trial of first-line bintrafusp Alfa in patients with locally advanced or persistent\/recurrent\/metastatic cervical cancer","volume":"30","author":"Oaknin","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjog.2024.07.014_bib90","doi-asserted-by":"crossref","DOI":"10.17305\/bb.2024.10528","article-title":"Efficacy and safety\u00a0of\u00a0bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients","author":"Yang","year":"2024","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.tjog.2024.07.014_bib91","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/JCMA.0000000000000629","article-title":"Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer","volume":"84","author":"Liu","year":"2021","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.tjog.2024.07.014_bib92","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/ijerph17072213","article-title":"Comparing paclitaxel-carboplatin with paclitaxel-cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer","volume":"17","author":"Huang","year":"2020","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.tjog.2024.07.014_bib93","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3390\/ijerph16234794","article-title":"Weekly dose-dense paclitaxel and triweekly low-dose cisplatin: a well-tolerated and effective chemotherapeutic regimen for first-line treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer","volume":"16","author":"Cheng","year":"2019","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.tjog.2024.07.014_bib94","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tjog.2020.03.001","article-title":"Dose-dense chemotherapy: a possible high cost-effectiveness treatment for ovarian cancer","volume":"59","author":"Huang","year":"2020","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2024.07.014_bib95","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jcph.1984","article-title":"Pharmacokinetic simulation analysis of less frequent nivolumab and pembrolizumab dosing: pharmacoeconomic rationale for dose deescalation","volume":"62","author":"Peer","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.tjog.2024.07.014_bib96","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ijc.33534","article-title":"Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer","volume":"149","author":"Low","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.tjog.2024.07.014_bib97","author":"Gangireddy"},{"key":"10.1016\/j.tjog.2024.07.014_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1357789","article-title":"Extended dosing (12 cycles) vs conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high-grade gliomas: a randomized, single-blind, two-arm, parallel-group controlled trial","volume":"14","author":"Anvari","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.tjog.2024.07.014_bib99","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000097943","article-title":"Maintenance or consolidation therapy in advanced ovarian cancer","volume":"70","author":"Pectasides","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.tjog.2024.07.014_bib100","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2024.07.014_bib101","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2024.07.014_bib102","first-page":"23","article-title":"The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer","volume":"7","author":"Martinez-Cannon","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.tjog.2024.07.014_bib103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455924002092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455924002092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:15:56Z","timestamp":1778580956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455924002092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1028455924002092"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2024.07.014","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2024.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}